Elon Musk’s brain chip firm Neuralink has received “breakthrough ... receive the designation so far this year, according to the FDA. Musk – who is known for making bold proclamations about ...

The boundary between science fiction and medical reality blurs as companies like Elon Musk's Neuralink make strides in ...

Elon Musk's brain chip firm Neuralink has said that the US Food and Drug Administration (FDA) has approved its first human clinical trial, a critical milestone after earlier struggles to gain ...

Elon Musk - who owns Neuralink, as well as Tesla ... work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology ...

Tech billionaire Elon Musk has claimed his Neuralink company ... the Food and Drug Administration (FDA), for comment. Neuralink has been criticised in the past, with Reuters reporting in December ...

Musk has business interests that depend heavily on government regulation, subsidies or policy, from Tesla’s electric cars to ...

Clinical trials of a wireless brain chip developed by Elon Musk’s Neuralink company will be tested ... most of our paperwork to the FDA,” he said, according to video from the event posted ...

Shortly after 2 a.m. on a Saturday in a midtown Manhattan sports bar packed with Aussies, Dr. Tom Oxley was feeling stunned.

Elon Musk said on Wednesday (30 November ... he hoped to start human trials this year. Neuralink has repeatedly missed internal deadlines to gain FDA approval to start human trials, current ...

Elon Musk's support for Trump could lead to significant policy shifts benefiting his companies. His potential role in the new ...

NEW YORK-- According to Elon Musk, the first human received an implant from his computer-brain interface company Neuralink over the ... inclusion criteria,” the FDA said Tuesday.

Elon Musk's secretive and futuristic brain-chip ... Musk later said the test monkeys live in "monkey paradise." The FDA rejected Neuralink's bid initially to launch human trials, citing concerns ...